{"links":{"html":"https://www.erudio.com/reports/durga-6-nct07735637","json":"https://www.erudio.com/reports/durga-6-nct07735637.json","markdown":"https://www.erudio.com/reports/durga-6-nct07735637.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"durga-6-07735637"}},"request":"https://www.erudio.com/contact?report=durga-6-07735637"},"offer":{"cited_commentary_sources":4,"verified_hcp_statements":61,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":6,"optional":true,"price_per_verified_person_usd":15,"price_usd":90,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"durga-6-nct07735637"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=durga-6-07735637","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/durga-6-nct07735637","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-30T17:55:32.194973Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the limitations; the sample findings; the report description."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":2},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Progression-Free Survival (PFS)"},{"claim_count":4,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":1,"title":"Primary endpoint: Minimal Residual Disease (MRD) negative Complete Response Rate (CRR)"},{"claim_count":2,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":10,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":14,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":2,"title":"Manufacturing speed and dual-target biological rationale"},{"claim_count":7,"coverage":"discussed","id":"A2","source_count":2,"title":"Local access, patient preference and early collaborative referral"},{"claim_count":5,"coverage":"discussed","id":"A3","source_count":2,"title":"Pre-apheresis treatment, bridging and lymphodepletion planning"},{"claim_count":5,"coverage":"discussed","id":"A4","source_count":2,"title":"Continuing care, caregiver support and outpatient feasibility"},{"claim_count":14,"coverage":"discussed","id":"A5","source_count":4,"title":"Future treatment roles, access expectations and uncertainty about a single replacement pathway"}],"counts":{"cited_sources":4,"claims_by_expression_type":{"comparison":4,"experience":9,"interpretation":10,"opinion":13,"question":1,"restatement":2,"uncertainty":3,"unspecified":19},"claims_by_kind":{"source_observation":61},"clinician_statements":57,"evidence_units":52,"findings":8,"people_cited":6,"people_identity_verified":6,"people_total":6,"screened_sources":14,"verified_claims":61},"findings_index":[{"id":"F1","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":6,"views":2},"has_counterview":true,"limitations":4,"links":{"context":7,"support":13},"ma_question":true,"named_voices":4,"passages":12,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"ASCT displacement is a forecast, not a settled replacement strategy"},{"id":"F2","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":3},"has_counterview":false,"limitations":4,"links":{"context":3,"support":4},"ma_question":true,"named_voices":1,"passages":4,"sources":1,"sources_by_kind":{"media":1}},"title":"Earlier Chinese frontline findings generate enthusiasm, but are not DURGA-6 outcomes"},{"id":"F3","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":3},"has_counterview":false,"limitations":3,"links":{"context":1,"support":4},"ma_question":true,"named_voices":2,"passages":4,"sources":1,"sources_by_kind":{"media":1}},"title":"Sustained MRD negativity is the interpretive priority, not a single negative sample"},{"id":"F4","structure":{"claims":6,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":0,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":3,"passages":4,"sources":2,"sources_by_kind":{"media":2}},"title":"Rapid manufacturing and dual targeting attract interest, while biological advantages remain hypotheses"},{"id":"F5","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":2,"questions":0,"restated":0,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":2,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Eligibility and access depend on fitness, manufacturing time, preference and early collaboration"},{"id":"F6","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":3,"questions":0,"restated":2,"views":0},"has_counterview":false,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"media":2}},"title":"The manufacturing interval remains a treatment-sequencing problem"},{"id":"F7","structure":{"claims":6,"claims_by_group":{"comparisons":2,"experience":1,"questions":0,"restated":2,"views":1},"has_counterview":true,"limitations":4,"links":{"context":0,"support":6},"ma_question":true,"named_voices":3,"passages":6,"sources":2,"sources_by_kind":{"media":2}},"title":"A single infusion and outpatient delivery do not eliminate continuing care"},{"id":"F8","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":7,"views":4},"has_counterview":false,"limitations":5,"links":{"context":1,"support":15},"ma_question":true,"named_voices":2,"passages":5,"sources":3,"sources_by_kind":{"media":3}},"title":"Early toxicity treatment is described as evolving institutional practice, not an AZD0120 protocol"}],"medical_affairs_question":"What evidence and support would make CAR-T a replacement for ASCT rather than another individualized consolidation option?","sections":{"analysis":[{"id":"section-1","level":2,"title":"ASCT displacement is a forecast, not a settled replacement strategy"},{"id":"section-2","level":2,"title":"Earlier Chinese frontline findings generate enthusiasm, not a DURGA-6 comparison"},{"id":"section-3","level":2,"title":"MRD interpretation turns on durability and evaluability"},{"id":"section-4","level":2,"title":"Rapid manufacturing has an operational rationale and separate biological hypotheses"},{"id":"section-5","level":2,"title":"Selection and access are conditional, with early referral distinct from treatment"},{"id":"section-6","level":2,"title":"The manufacturing interval requires sequencing and interim disease control"},{"id":"section-7","level":2,"title":"One infusion still entails ongoing care, support and proximity"},{"id":"section-8","level":2,"title":"Toxicity management is institutional and evolving"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Progression-Free Survival (PFS)"},{"findings":[{"id":"F3","shared_claims":4}],"id":"T2","label":"Primary endpoint: Minimal Residual Disease (MRD) negative Complete Response Rate (CRR)"},{"findings":[{"id":"F2","shared_claims":2}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":5},{"id":"F7","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":13}],"id":"T6","label":"Safety and tolerability"},{"findings":[],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-30T17:55:32.194973Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-30T18:07:32Z","record_hash":"52317c99cd655eed644233d77701c9ba5452858a945e7800bde996e469b54f54","release_hash":"d403eadb649c8c187db8b68808b8f3d2d79c7a9d805aab97ab66c180db60a0b1","report_id":"erudio-nct07735637","run_id":"b42a491f-0174-4e21-9783-870175f205d2","schema_version":"5.0","slug":"durga-6-07735637","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"DURGA-6 compares AZD0120 CAR-T consolidation with autologous stem cell transplantation in transplant-eligible patients with newly diagnosed multiple myeloma. Commentary comes from X posts, a podcast and YouTube discussions featuring physicians, including medical oncologists, and a hematology–oncology nurse practitioner. Debate centers on whether CAR-T will displace transplantation, an unsettled prospect, and how sustained MRD negativity should be interpreted. Another question is whether rapid manufacturing offers biological advantages, which remain hypothetical in these discussions.","meta_description":"14 sources screened · 61 verified statements (57 from clinicians verified by NPI or staff page) from 4 sources · 8 findings. Updated Oct 30, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-d025b5b902e27ea4b04e","claim-ad1221d6c875480a8740","claim-c0706ea15c3de2e7cfac"],"id":"F3","paraphrase":"In a YouTube discussion, a medical oncologist asked how sustained MRD negativity should be interpreted in the earlier Chinese frontline study.","source_channel":"youtube","source_date":"2026-08-03","title":"Sustained MRD negativity is the interpretive priority, not a single negative sample"},{"cited_claim_ids":["claim-d24b3d1bc9b95682f3f7","claim-fde2776f51ff5f72e93f","claim-1a3d6c1cd7859ca7fb02","claim-147152cf4054835b018f"],"id":"F4","paraphrase":"In the YouTube discussion, the same medical oncologist asked whether FasT-CAR manufacturing could improve efficacy in addition to shortening production time.","source_channel":"youtube","source_date":"2026-08-03","title":"Rapid manufacturing and dual targeting attract interest, while biological advantages remain hypotheses"}]},"publication":{"approved_at":"2026-10-30T18:07:32Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-30T23:42:06Z","summary":"Corrected to match the delivered report: the limitations; the sample findings; the report description."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":14},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","76 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition provide perspectives from a small set of conversations, not a representative measure of HCP opinion. Podcast and video versions of the ONS session must not be counted as independent support.","No publication of results for NCT07735637 was found, and no protocol was available among the sources reviewed. The report cannot establish comparative efficacy, trial-specific safety or detailed protocol requirements.","Earlier Chinese frontline findings include both transplant-eligible and transplant-ineligible patients. Their favorable interpretation does not establish benefit over ASCT in DURGA-6.","Several treatment-choice statements do not name DURGA-6. They are contextual views on the relevant clinical decision, not direct evaluations of the trial's outcomes or conduct.","Some podcast remarks about future treatment roles do not identify who spoke. Those passages remain unnamed and are not treated as additional independent views.","Discussion using unnamed trial references, alternative terminology or different transcriptions may be missing, and some additional X material was not fully assessed.","No exact AZD0120 product label was located, and the broader regulatory review was incomplete. General CAR-T practices in these discussions cannot be treated as AZD0120 prescribing instructions.","The safety discussion is selective: the institutional policy on prophylactic tocilizumab and concerns about prolonged cytopenias, clonal marrow changes and secondary malignancies are not characterized here. This limits conclusions about preventive care and long-term safety.","Not yet captured in this edition: a view on geographic CAR T access barriers and developing CAR T capacity at transplant centers."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":1,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":4},"count":4,"evidence_window":{"end":"2026-09-23","start":"2026-08-03"},"retrieval_snapshot":"2026-10-30T17:00:48.308727Z","timeline":[{"count":3,"week":"2026-W32"},{"count":1,"week":"2026-W39"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07735637:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07735637:context","quote_policy":"short_quote_link_out"},{"id":"openfda:c961a1ac-6705-4756-9abc-9d84a6fcb5c8:20260903","quote_policy":"short_quote_link_out"},{"id":"openfda:cf5255cc-91fd-4132-973b-764dba142eae:20241014","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:fdc599","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2083672032433127605:d8a1571d-e5b5-45bd-9d20-f1a9ec741bd1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084187372418408879:a4bd45d6-10e4-4dea-bd5d-bfa2c7c9e094","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088745176697360521:293f4a00-d56c-4217-98f0-127055c17376","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089385892511191537:09c75150-53c4-45ad-ae11-2eeb4e253ec8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098803746012586167:dd739f78-0b9a-4126-84f9-c062b8b44b51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102695011024351308:35ef0bde-aeb8-4ec2-9928-ad6896e75168","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102699827067056545:4b922436-f2bf-4f12-86aa-6122d8524585","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102712236393336955:7097b176-0df4-4fa2-98fd-d65a950fe493","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102780212161437941:5e944804-e3bf-49c3-ac30-276edf09f4b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102783384539803978:cc1634a4-ebd2-440e-8718-bdd2420cb3be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103486963638755739:041eda51-5187-4049-9019-ffcc66f4dda4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:D_lkHztkljA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:KBvEqL1OPcc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":11,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":14},"count":14,"evidence_window":{"end":"2026-09-27","start":"2026-08-01"},"retrieval_snapshot":"2026-10-30T17:00:48.308727Z","timeline":[{"count":1,"week":"2026-W31"},{"count":4,"week":"2026-W32"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W34"},{"count":1,"week":"2026-W37"},{"count":6,"week":"2026-W39"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: azd0120","status":"unmapped"},{"brand_names":["Cytoxan","Frindovyx","Neosar"],"label":"cyclophosphamide","slug":"cyclophosphamide"},{"brand_names":["Fludara","Oforta"],"label":"fludarabine","slug":"fludarabine"},{"reason":"Unmapped registry intervention: melphalan (part of asct)","status":"unmapped"},{"brand_names":["Revlimid"],"label":"lenalidomide","slug":"lenalidomide"}],"indications":[{"reason":"Unmapped registry condition: Newly Diagnosed Multiple Myeloma (NDMM)","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"DURGA-6","aliases":["DURGA-6","A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).","A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (DURGA-6)"],"brief_title":"A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Newly Diagnosed Multiple Myeloma (NDMM)"],"display_condition":"transplant-eligible newly diagnosed multiple myeloma","display_interventions":[["AZD0120"]],"enrollment":{"count":750,"type":"ESTIMATED"},"interventions":[{"name":"AZD0120","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"},{"name":"Cyclophosphamide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Fludarabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Melphalan (part of ASCT)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Lenalidomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07735637","official_title":"A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (DURGA-6)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-11-02","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as time from randomisation until progression as assessed by Blinded Independent Central Review, or death due to any cause, whichever occurs first.","measure":"Progression-Free Survival (PFS)","timeFrame":"Up to approximately 13 years."},{"description":"MRD negative CRR is defined as the proportion of participants with a MRD negative status and who have a response of CR or a stringent CR.","measure":"Minimal Residual Disease (MRD) negative Complete Response Rate (CRR)","timeFrame":"Up to approximately 13 years."}],"registered_date":{"date":"2026-07-30","type":"ACTUAL"},"registry_last_updated":"2026-10-21","registry_url":"https://clinicaltrials.gov/study/NCT07735637","short_name":"DURGA-6","short_name_basis":"registry_acronym","sponsor":"AstraZeneca","start_date":{"date":"2026-09-24","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"D8316C00001","type":"sponsor_study_id"},{"domain":"AstraZeneca","id":"AZD0120","type":"other"}],"study_type":"INTERVENTIONAL"}}}